{"pageContent": "Background: Both docetaxel and androgen-receptor-axis-targeted (ARAT) agents are approved in metastatic castration-sensitive prostate cancer (mCSPC) patients. Predictive factors of therapy efficacy are lacking.", "metaData": {"source": "Piloting prostate cancer patient-reported outcomesin clinical practice\nhttps://pubmed.ncbi.nlm.nih.gov/26498748/"}}